Influence of frequent infectious exposures on general and varicella-zoster virus-specific immune responses in pediatricians

Clinical and Vaccine Immunology

Volumn 21, Issue 3, 2014, Pages 417-426

  Ogunjimi, Benson ^a,b,c   Smits, Evelien ^a   Heynderickx, Steven ^a,c   Van Den Bergh, Johan ^a   Bilcke, Joke ^a   Jansens, Hilde ^c   Malfait, Ronald ^c   Ramet, Jose ^c   Maecker, Holden T ^d   Cools, Nathalie ^a   Beutels, Philippe ^a,e   Van Damme, Pierre ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN E; INTERLEUKIN 2; PROTEIN IE62; PROTEIN IE63; TETANUS TOXIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS; EFFECTOR CELL; FEMALE; HERPES ZOSTER; HUMAN; HUMAN ADENOVIRUS 5; HUMORAL IMMUNITY; IMMUNE RESPONSE; LEUKOCYTE COUNT; MALE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; VARICELLA ZOSTER VIRUS; VIRUS DETECTION; VIRUS LOAD;

ADENOVIRUSES, HUMAN; ADULT; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; CYTOKINES; CYTOMEGALOVIRUS; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PHYSICIANS; T-LYMPHOCYTES; TETANUS TOXIN;

EID: 84896790408     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00818-13     Document Type: Article

References (70)

1. Amanna IJ, Slifka MK. 2010. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol. Rev. 236:125-138. http://dx.doi.org/10.1111/j.1600-065X.2010.00912.x.
2. Radbruch A, Muehlinghaus G, Luger EO, Inamine A, Smith KG, Dörner T, Hiepe F. 2006. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6:741-750. http://dx.doi.org/10.1038/ nri1886. (Pubitemid 44453460)
3. Hope-Simpson RE. 1965. The nature of herpes zoster: a long-term study and a new hypothesis. Proc. R. Soc. Med. 58:9-20.
4. Bilcke J, van Hoek AJ, Beutels P. 2013. Childhood varicella-zoster virus vaccination in Belgium: cost-effective only in the long run or without exogenous boosting? Hum. Vaccin. Immunother. 9:812-822. http://dx.doi.org/10.4161/jv. 23334.
5. Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G. 2000. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol. Infect. 125:651- 669. http://dx.doi.org/10.1017/S0950268800004714.
6. Schuette MC, Hethcote HW. 1999. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull. Math. Biol. 61:1031-1064. http://dx.doi.org/10.1006/bulm.1999.0126.
7. Gershon AA, Steinberg SP, Borkowsky W, Lennette D, Lennette E. 1982. IgM to varicella-zoster virus: demonstration in patients with and without clinical zoster. Pediatr. Infect. Dis. 1:164-167. http://dx.doi.org/10.1097/00006454- 198205000-00007.
8. Arvin AM, Koropchak CM, Wittek AE. 1983. Immunologic evidence of reinfection with varicella-zoster virus. J. Infect. Dis. 148:200-205. http://dx.doi.org/10.1093/infdis/148.2.200. (Pubitemid 13002453)
9. Gershon AA, Steinberg SP. 1990. Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. J. Infect. Dis. 161:661-666.
10. Garnett GP, Grenfell BT. 1992. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol. Infect. 108: 513-528. http://dx.doi.org/10.1017/S0950268800050019.
11. Terada K, Kawano S, Yoshihiro K, Morita T. 1993. Proliferative response to varicella-zoster virus is inverse related to development of high levels of varicella-zoster virus specific IgG antibodies. Scand. J. Infect. Dis. 25:775-778. http://dx.doi.org/10.3109/00365549309008578. (Pubitemid 24017091)
12. Solomon BA, Kaporis AG, Glass AT, Simon SI, Baldwin HE. 1998. Lasting immunity to varicella in doctors study (L.I.V.I.D. study). J. Am. Acad. Dermatol. 38:763-765. http://dx.doi.org/10.1016/S0190-9622(98)70207-5. (Pubitemid 28213723)
13. Terada K, Niizuma T, Yagi Y, Miyashima H, Kataoka N, Sadahiro T. 2000. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination. J. Med. Virol. 62:46-51. http://dx.doi.org/10.1002/1096- 9071(200009)62:1<46::AID-JMV8>3.0.CO;2-Y.
14. Brisson M, Gay NJ, Edmunds WJ, Andrews NJ. 2002. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20:2500-2507. http://dx.doi.org/10.1016/S0264-410X(02)00180- 9. (Pubitemid 34615588)
15. Thomas SL, Wheeler JG, Hall AJ. 2002. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360:678-682. http://dx.doi.org/10.1016/S0140-6736(02)09837-9. (Pubitemid 35232336)
16. Vossen MT, Gent MR, Weel JF, de Jong MD, van Lier RA, Kuijpers TW. 2004. Development of virus-specific CD4+ T cells on reexposure to varicella-zoster virus. J. Infect. Dis. 190:72-82. http://dx.doi.org/10.1086/421277. (Pubitemid 38858406)
17. Jumaan AO, Yu O, Jackson LA, Bohlke K, Galil K, Seward JF. 2005. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J. Infect. Dis. 191:2002-2007. http://dx.doi.org/10.1086/430325. (Pubitemid 40800569)
18. Mullooly JP, Riedlinger K, Chun C, Weinmann S, Houston H. 2005. Incidence of herpes zoster, 1997-2002. Epidemiol. Infect. 133:245-253. http://dx.doi.org/10.1017/S095026880400281X. (Pubitemid 40439304)
19. Yavuz T, Ozdemir I, Sencan I, Arbak P, Behçet M, Sert E. 2005. Seroprevalence of varicella, measles and hepatitis B among female health care workers of childbearing age. Jpn. J. Infect. Dis. 58:383-386. (Pubitemid 43078740)
20. Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, Seward JF. 2005. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 5:68. http://dx.doi.org/10.1186/1471-2458-5-68.
21. Chaves SS, Santibanez TA, Gargiullo P, Guris D. 2007. Chickenpox exposure and herpes zoster disease incidence in older adults in the U.S. Public Health Rep. 122:155-159.
22. Saadatian-Elahi M, Mekki Y, Del Signore C, Lina B, Derrough T, Caulin E, Thierry J, Vanhems P. 2007. Seroprevalence of varicella antibodies among pregnant women in Lyon-France. Eur. J. Epidemiol. 22:405-409. http://dx.doi.org/10.1007/s10654-007-9136-z. (Pubitemid 47052083)
23. Bonmarin I, Santa-Olalla P, Lévy-Bruhl D. 2008. Modelling the impact of vaccination on the epidemiology of varicella zoster virus. Rev. Epidemiol. Sante Publique 56:323-331. (In French.) http://dx.doi.org/10.1016/j. respe.2008.07.087.
24. Patel MS, Gebremariam A, Davis MM. 2008. Herpes zoster-related hospitalizations and expenditures before and after introduction of the varicella vaccine in the United States. Infect. Control Hosp. Epidemiol. 29:1157-1163. http://dx.doi.org/10.1086/591975.
25. Valdarchi C, Farchi F, Dorrucci M, De Michetti F, Paparella C, Babudieri S, Spano A, Starnini G, Rezza G. 2008. Epidemiological investigation of a varicella outbreak in an Italian prison. Scand. J. Infect. Dis. 40:943-945. http://dx.doi.org/10.1080/00365540802308449.
26. Toyama N, Shiraki K, Society of the Miyazaki Prefecture Dermatologists. 2009. Epidemiology of herpes zoster and its relationship to varicella in Japan: a 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J. Med. Virol. 81:2053-2058. http://dx.doi.org/10.1002/jmv.21599.
27. Brisson M, Melkonyan G, Drolet M, De Serres G, Thibeault R, De Wals P. 2010. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 28:3385-3397. http://dx.doi.org/ 10.1016/j.vaccine.2010.02.079.
28. Carville KS, Riddell MA, Kelly HA. 2010. A decline in varicella but an uncertain impact on zoster following varicella vaccination in Victoria, Australia. Vaccine 28: 2532-2538. http://dx.doi.org/10.1016/j.vaccine.2010.01. 036.
29. Donahue JG, Kieke BA, Gargiullo PM, Jumaan AO, Berger NR, Mc-Cauley JS, Belongia EA. 2010. Herpes zoster and exposure to the varicella zoster virus in an era of varicella vaccination. Am. J. Public Health 100: 1116-1122. http://dx.doi.org/10.2105/AJPH.2009.160002.
30. Grant KA, Carville KS, Kelly HA. 2010. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med. J. Aust. 193:483.
31. Karhunen M, Leino T, Salo H, Davidkin I, Kilpi T, Auranen K. 2010. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol. Infect. 138:469-481. http://dx.doi.org/10.1017/S0950268809990768.
32. Nelson MR, Britt HC, Harrison CM. 2010. Evidence of increasing frequency of herpes zoster management in Australian general practice since the introduction of a varicella vaccine. Med. J. Aust. 193:110-113.
33. Rimland D, Moanna A. 2010. Increasing incidence of herpes zoster among veterans. Clin. Infect. Dis. 50:1000-1005. http://dx.doi.org/10.1086/651078.
34. Wu CY, Hu HY, Huang N, Pu CY, Shen HC, Chou YJ. 2010. Do the health-care workers gain protection against herpes zoster infection? A 6-year population-based study in Taiwan. J. Dermatol. 37:463-470. http://dx.doi.org/10. 1111/j.1346-8138.2010.00804.x.
35. Gaillat J, Gajdos V, Launay O, Malvy D, Demoures B, Lewden L, Pinchinat S, Derrough T, Sana C, Caulin E, Soubeyrand B. 2011. Does monastic life predispose to the risk of Saint Anthony's fire (herpes zoster)? Clin. Infect. Dis. 53:405-410. http://dx.doi.org/10.1093/cid/cir436.
36. Jardine A, Conaty SJ, Vally H. 2011. Herpes zoster in Australia: evidence of increase in incidence in adults attributable to varicella immunization? Epidemiol. Infect. 139:658 - 665. http://dx.doi.org/10.1017/S0950268810001949.
37. Leung J, Harpaz R, Molinari NA, Jumaan A, Zhou F. 2011. Herpes zoster incidence among insured persons in the United States, 1993-2006: evaluation of impact of varicella vaccination. Clin. Infect. Dis. 52:332-340. http://dx.doi.org/10.1093/cid/ciq077.
38. Ogunjimi B, Smits E, Hens N, Hens A, Lenders K, Ieven M, Van Tendeloo V, Van Damme P, Beutels P. 2011. Exploring the impact of exposure to primary varicella in children on varicella-zoster virus immunity of parents. Viral Immunol. 24:151-157. http://dx.doi.org/10.1089/vim.2010.0031.
39. Salleras M, Domínguez A, Soldevila N, Prat A, Garrido P, Torner N, Borrás E, Salleras L. 2011. Contacts with children and young people and adult risk of suffering herpes zoster. Vaccine 29:7602-7605. http://dx.doi.org/10.1016/j.vaccine.2011.08.023.
40. Tanuseputro P, Zagorski B, Chan KJ, Kwong JC. 2011. Population-based incidence of herpes zoster after introduction of a publicly funded varicella vaccination program. Vaccine 29:8580-8584. http://dx.doi.org/10.1016/j.vaccine. 2011.09.024.
41. van Hoek AJ, Melegaro A, Zagheni E, Edmunds WJ, Gay N. 2011. Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England. Vaccine 29:2411-2420. http://dx.doi.org/10.1016/j.vaccine.2011.01.037.
42. Carville KS, Grant KA, Kelly HA. 2012. Herpes zoster in Australia. Epidemiol. Infect. 140:599-600 (Author reply, 600-601). http://dx.doi.org/10. 1017/S095026881100149X.
43. Chao DY, Chien YZ, Yeh YP, Hsu PS, Lian IB. 2012. The incidence of varicella and herpes zoster in Taiwan during a period of increasing varicella vaccine coverage, 2000-2008. Epidemiol. Infect. 140:1131-1140. http://dx.doi.org/10.1017/S0950268811001786.
44. Lasserre A, Blaizeau F, Gorwood P, Bloch K, Chauvin P, Liard F, Blanchon T, Hanslik T. 2012. Herpes zoster: family history and psychological stress-case-control study. J. Clin. Virol. 55:153-157. http://dx.doi.org/10. 1016/j.jcv.2012.06.020.
45. Ogunjimi B, Van Damme P, Beutels P. 2012. Zoster in monasteries: some clarification needed. Clin. Infect. Dis. 54:305-306 (Author reply, 306-307). http://dx.doi.org/10.1093/cid/cir841.
46. Hales CM, Harpaz R, Joesoef MR, Bialek SR. 2013. Examination of links between herpes zoster incidence and childhood varicella vaccination. Ann. Intern. Med. 159:739-745. http://dx.doi.org/10.7326/0003-4819-159-11-201312030- 00006.
47. Ogunjimi B, Van Damme P, Beutels P. 2013. Herpes zoster risk reduction through exposure to chickenpox patients: a systematic multidisciplinary review. PLoS One 8:e66485. http://dx.doi.org/10.1371/journal.pone.0066485.
48. Ogunjimi B, Peeters D, Hens N, Malfait R, Van Tendeloo V, Van Damme P, Beutels P, Smits E. 2012. Sampling site matters when counting lymphocyte subpopulations. PLoS One 7:e41405. http://dx.doi.org/10.1371/journal.pone. 0041405.
49. Ogunjimi B, Hens N, Malfait R, Van Tendeloo V, Smits E. 2013. Creating a robust framework for the analysis of cryopreserved samples in quantitative immunological experiments. J. Immunol. Methods 392:63-67. http://dx.doi.org/10. 1016/j.jim.2013.03.006.
50. de Villemeur AB, Gratacap-Cavallier B, Casey R, Baccard-Longère M, Goirand L, Seigneurin JM, Morand P. 2011. Occupational risk for cytomegalovirus, but not for parvovirus B19 in child-care personnel in France. J. Infect. 63:457-467. http://dx.doi.org/10.1016/j.jinf.2011.06.012.
51. Levin MJ, Schmader KE, Gnann JW, McNeil SA, Vesikari T, Betts RF, Keay S, Stek JE, Bundick ND, Su SC, Zhao Y, Li X, Chan IS, Annunziato PW, Parrino J. 2013. Varicella-zoster virus specific antibody responses in 50-59-year-old recipients of zoster vaccine J. Infect. Dis. 208: 1386-1390. http://dx.doi.org/10.1093/infdis/jit342.
52. Leroux-Roels I, Leroux-Roels G, Clement F, Vandepapelière P, Vassilev V, Ledent E, Heineman TC. 2012. A phase 1/2 clinical trial evaluating safety and immunogenicity of a varicella zoster glycoprotein e subunit vaccine candidate in young and older adults. J. Infect. Dis. 206:1280-1290. http://dx.doi.org/10.1093/infdis/jis497.
53. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A, Veterans Affairs Cooperative Studies Program Shingles Prevention Study Investigators. 2008. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197:825-835. http://dx.doi.org/10.1086/528696. (Pubitemid 351417005)
54. Jenke AC, Klein S, Baiker A, Wirth S, Sander M, Noelting C, Boecher O, Vizoso-Pinto MG. 2012. Serologic analysis of the IgG antibody response in children with varicella zoster virus wild-type infection and vaccination. Pediatr. Infect. Dis. J. 31:1148-1152. http://dx.doi.org/10.1097/INF. 0b013e31826bac27.
55. + T cell response to IE62, by use of IE62 peptides after varicella vaccination. J. Infect. Dis. 188:40-52. http://dx.doi.org/10.1086/375828.
56. + T cells specific for immediate-early 63 protein of varicellazoster virus. Eur. J. Immunol. 37:3393-3403. http://dx.doi.org/10.1002/ eji.200737648.
57. + T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin. Exp. Immunol. 152: 522-531. http://dx.doi.org/10.1111/j.1365-2249.2008.03633.x.
58. Malavige GN, Rohanachandra LT, Jones L, Crack L, Perera M, Fernando N, Guruge D, Ogg GS. 2010. IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies. Br. J. Cancer 102:727-730. http://dx.doi.org/10.1038/sj.bjc. 6605542.
59. Zerboni L, Sobel RA, Ramachandran V, Rajamani J, Ruyechan W, Abendroth A, Arvin A. 2010. Expression of varicella-zoster virus immediate-early regulatory protein IE63 in neurons of latently infected human sensory ganglia. J. Virol. 84:3421-3430. http://dx.doi.org/10.1128/JVI.02416-09.
60. Nagel MA, Choe A, Traktinskiy I, Cordery-Cotter R, Gilden D, Cohrs RJ. 2011. Varicella-zoster virus transcriptome in latently infected human ganglia. J. Virol. 85:2276-2287. http://dx.doi.org/10.1128/JVI.01862-10.
61. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255:27-40. http://dx.doi.org/10.1016/S0022- 1759(01)00416-1.
62. Weinberg A, Zhang JH, Oxman MN, Johnson GR, Hayward AR, Caulfield MJ, Irwin MR, Clair J, Smith JG, Stanley H, Marchese RD, Harbecke R, Williams HM, Chan IS, Arbeit RD, Gershon AA, Schodel F, Morrison VA, Kauffman CA, Straus SE, Schmader KE, Davis LE, Levin MJ, U.S. Department of Veterans Affairs (VA) Cooperative Studies Program Shingles Prevention Study Investigators. 2009. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J. Infect. Dis. 200:1068-1077. http://dx.doi.org/10.1086/605611.
63. Weinberg A, Lazar AA, Zerbe GO, Hayward AR, Chan IS, Vessey R, Silber JL, MacGregor RR, Chan K, Gershon AA, Levin MJ. 2010. Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses. J. Infect. Dis. 201:1024-1030. http://dx.doi.org/10.1086/651199.
64. Irwin MR, Levin MJ, Laudenslager ML, Olmstead R, Lucko A, Lang N, Carrillo C, Stanley HA, Caulfield MJ, Weinberg A, Chan IS, Clair J, Smith JG, Marchese RD, Williams HM, Beck DJ, McCook PT, Zhang JH, Johnson G, Oxman MN. 2013. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin. Infect. Dis. 56:1085-1093. http://dx.doi.org/10.1093/cid/cis1208.
65. Weinberg A, Huang S, Song LY, Fenton T, Williams P, Patterson J, Tovar-Salazar A, Levin MJ. 2012. Immune correlates of herpes zoster in HIV-infected children and youth. J. Virol. 86:2878-2881. http://dx.doi.org/10. 1128/JVI.06623-11.
66. + T cells in seronegative donors. PLoS One 7: e31420. http://dx.doi.org/10.1371/journal.pone.0031420.
67. Heller T, Werner JM, Rahman F, Mizukoshi E, Sobao Y, Gordon AM, Sheets A, Sherker AH, Kessler E, Bean KS, Herrine SK, Stevens M, Schmitt J, Rehermann B. 2013. Occupational exposure to hepatitis C virus: early T-cell responses in the absence of seroconversion in a longitudinal cohort study. J. Infect. Dis. 208:1020-1025. http://dx.doi.org/10.1093/infdis/jit270.
68. Gillespie GM, Wills MR, Appay V, O'Callaghan C, Murphy M, Smith N, Sissons P, Rowland-Jones S, Bell JI, Moss PA. 2000. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J. Virol. 74:8140-8150. http://dx.doi.org/10.1128/JVI.74. 17.8140-8150.2000. (Pubitemid 30642582)
69. Khan N, Shariff N, Cobbold M, Bruton R, Ainsworth JA, Sinclair AJ, Nayak L, Moss PA. 2002. Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J. Immunol. 169:1984-1992. (Pubitemid 34857662)
70. Ogunjimi B, Theeten H, Hens N, Beutels P. Serology indicates cytomegalovirus infection is associated with varicella-zoster virus reactivation. J. Med. Virol., in press. http://dx.doi.org/10.1002/jmv.23749.